a tyrosine kinase protein interaction map reveals targetable egfr network oncogenesis in lung cancer
Published Streamed 2 years ago • 69 plays • Length 32:40Download video MP4
Download video MP3
Similar videos
-
3:47
the egf receptor tyrosine protein kinases
-
0:17
afatinib inhibits egfr receptor activation
-
2:54
protein kinases: cell signaling and phosphorylation
-
11:24
oncogenetics - mechanism of cancer (tumor suppressor genes and oncogenes)
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
6:02
egfr mutation and cancer
-
13:17
rtks (receptor tyrosine kinases) and their role in cancer
-
4:14
receptor tyrosine kinases - rtk
-
1:57
the egf receptor tyrosine protein kinases and the therapy of tumors with activated egf receptors. 02
-
0:52
selecting egfr tyrosine kinase inhibitors for egfr-mutant lung cancer
-
11:53
insight 2: a phase ii study of tepotinib plus osimertinib in met-amplified nsclc
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
5:32
introduction to egfr inhibitors
-
55:27
induction of receptor tyrosine kinase signaling from lung adenocarcinoma
-
0:30
emerging data on immunotherapies and tyrosine kinase inhibitors in lung cancer: 2022 esmo florida
-
0:37
response to systemic anti-cancer therapy in uncommon egfr mutations
-
3:59
role of the map kinase pathway in nsclc
-
1:41
egfr mutations in patients with lung cancer
-
14:39
egfr family and cancer
-
2:38
what does egfr-positive lung cancer mean?